Table 1 Distribution of baseline characteristics in the experimental arm and the control arm

Type of treatment

0.98^a

 Radiotherapy alone

9 (36)

10 (36)

 Radio-chemotherapy

16 (64)

18 (64)

Radiotherapy dose

0.77^a

 60 Gy

9 (36)

9 (32)

 64–70 Gy

16 (64)

19 (68)

Type of chemotherapy

0.90^a

 Cisplatin, 2 cycles of 5 × 20 or 4 × 25 mg/m²

6 (38)

9 (50)

 Cisplatin, 2–3 cycles of 1 × 100 mg/m²

3 (19)

3 (17)

 Cisplatin, 40 mg/m² weekly

6 (38)

5 (28)

 Carboplatin (4 × AUC 1.5 / 5 × AUC 1.0)

1 (6)

1 (6)

Tumor site

0.80^a

 Hypopharynx

3 (12)

2 (7)

 Larynx

4 (16)

3 (11)

 Oral cavity

5 (20)

8 (29)

 Oropharynx

13 (52)

15 (54)

Tumor site (combined)

0.51^b

 Hypopharynx, larynx

7 (28)

5 (18)

 Oropharynx, oral cavity

18 (72)

23 (82)

Gender

0.16^b

 Female

7 (28)

3 (11)

 Male

18 (72)

25 (89)

Age at start of radiotherapy

0.27^a

 ≤ 59 years

15 (60)

12 (43)

 ≥ 60 years

10 (40)

16 (57)

ECOG performance status

0.56^a

 0

16 (64)

20 (71)

 ≥ 1

9 (36)

8 (29)

Primary tumor stage

0.75^a

 T1-2

10 (40)

10 (36)

 T3-4

15 (60)

18 (64)

Nodal stage

0.93^a

 N0-1

14 (56)

16 (57)

 N2-3

11 (44)

12 (43)

HPV-status

0.40^a

 Negative

8 (32)

9 (32)

 Positive

11 (33)

16 (57)

 Unknown

6 (34)

3 (11)

Upfront surgery

0.82^a

 No

6 (24)

6 (21)

 Yes

19 (76)

22 (79)

Neck Dissection

0.96^a

 Bilateral

9 (36)

9 (32)

 Unilateral

10 (40)

12 (43)

 No

6 (24)

7 (25)